Please assess the completion status of the following clinical trial:

Trial Title: Abatacept for Treatment of Recurrent or de Novo Autoimmune Hepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria for de novo AIH~* Age 18 or older~* Patients who have biopsy evidence of autoimmune liver disease following liver transplantation and a different pre-transplant etiology of liver disease will be eligible.~* Patients who have been treated with steroids or other immunosuppressive agents for at least a month and who have not responded either with respect to normalization of liver function tests or biopsy evidence of hepatitis will be eligible.~* Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure.~* Women of child bearing potential agree to have pregnancy test at screening~* Males agree use of appropriate contraceptives during the active Orenia dosing period~Inclusion Criteria for recurrent AIH~* Age 18 or older~* Patients who have biopsy evidence of autoimmune liver disease following liver transplantation and whose original etiology of liver disease was AIH will be eligible.~* Patients who have been treated with steroids or other immunosuppressive agents for at least a month and who have not responded either with respect to normalization of liver function tests or biopsy evidence of hepatitis will be eligible.~* Ability to provide signed and dated IRB approved written consent in accordance with regulatory and institutional guidelines prior to any protocol-related procedure.~* Women of child bearing potential agree to have pregnancy test at screening~* Males agree use of appropriate contraceptives during the active Orenia dosing period~Exclusion Criteria:~* Active systemic infection~* Allergy to abatacept~* Known malignancy in the previous 2 years except for non-melanoma skin cancer~* Pregnancy or breast feeding~* Inability to commit to complete treatment protocol at Duke, as all procedures must be completed at Duke~* Prisoners or those who are compulsory detained~* Inability to read and understand English~* EBV seronegative (if not tested within 2 years prior to study enrollment, then testing will be done prior to study enrollment, results must be positive for study participation)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orencia® (Abatacept) (Type: EXPERIMENTAL): Abatacept 125 mg, subcutaneous once a week for 6 months or up to one year if subject has a favorable response

Based on this trial design, predict the completion outcome and termination type (if applicable).